John D. Hainsworth

57.6k total citations · 10 hit papers
631 papers, 37.1k citations indexed

About

John D. Hainsworth is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, John D. Hainsworth has authored 631 papers receiving a total of 37.1k indexed citations (citations by other indexed papers that have themselves been cited), including 434 papers in Oncology, 229 papers in Pulmonary and Respiratory Medicine and 124 papers in Pathology and Forensic Medicine. Recurrent topics in John D. Hainsworth's work include Lung Cancer Research Studies (136 papers), Cancer Treatment and Pharmacology (119 papers) and Lung Cancer Treatments and Mutations (118 papers). John D. Hainsworth is often cited by papers focused on Lung Cancer Research Studies (136 papers), Cancer Treatment and Pharmacology (119 papers) and Lung Cancer Treatments and Mutations (118 papers). John D. Hainsworth collaborates with scholars based in United States, United Kingdom and France. John D. Hainsworth's co-authors include F. Anthony Greco, Herbert I. Hurwitz, Louis Fehrenbacher, Fairooz F. Kabbinavar, W. Heim, William Novotny, Jordan Berlin, Eric Holmgren, Thomas H. Cartwright and Howard A. Burris and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

John D. Hainsworth

623 papers receiving 36.0k citations

Hit Papers

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin... 1997 2026 2006 2016 2004 2012 2012 2011 2005 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
    2004 8.4k citations John D. Hainsworth et al. New England Journal of Medicine profile →
  2. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
    2012 3.3k citations Andrew J. Armstrong, John D. Hainsworth et al. New England Journal of Medicine profile →
  3. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
    2012 1.0k citations Aleksandar Sekulić, Michael R. Migden et al. New England Journal of Medicine profile →
  4. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
    2011 767 citations Marianne Pavel, John D. Hainsworth et al. profile →
  5. Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
    2005 550 citations John D. Hainsworth et al. Journal of Clinical Oncology profile →
  6. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
    1997 513 citations John D. Hainsworth et al. Journal of Clinical Oncology profile →
  7. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
    2015 509 citations Carla Casulo, Michelle Byrtek et al. Journal of Clinical Oncology profile →
  8. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
    2019 383 citations Funda Meric‐Bernstam, Charles Swanton et al. The Lancet Oncology profile →
  9. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
    2018 357 citations John D. Hainsworth, Funda Meric‐Bernstam et al. Journal of Clinical Oncology profile →
  10. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
    2021 251 citations Milind Javle, Mitesh J. Borad et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John D. Hainsworth United States 82 21.5k 12.3k 10.1k 7.0k 5.3k 631 37.1k
Janet Dancey United States 68 19.9k 0.9× 15.4k 1.3× 8.6k 0.8× 3.3k 0.5× 5.5k 1.0× 205 38.3k
Howard A. Burris United States 89 25.4k 1.2× 10.7k 0.9× 13.0k 1.3× 3.8k 0.5× 4.2k 0.8× 741 38.2k
Armando Santoro Italy 87 17.8k 0.8× 13.8k 1.1× 5.6k 0.6× 8.8k 1.3× 3.8k 0.7× 924 34.7k
Richard Kaplan United Kingdom 48 22.4k 1.0× 20.2k 1.6× 7.3k 0.7× 3.9k 0.6× 7.8k 1.5× 173 46.0k
Salvatore Siena Italy 76 26.8k 1.2× 12.2k 1.0× 7.6k 0.7× 8.5k 1.2× 4.7k 0.9× 534 37.8k
M. van Glabbeke Belgium 65 15.5k 0.7× 18.4k 1.5× 4.5k 0.4× 4.4k 0.6× 9.7k 1.8× 198 36.0k
Heinz‐Josef Lenz United States 83 24.6k 1.1× 9.2k 0.7× 9.7k 1.0× 8.2k 1.2× 5.4k 1.0× 860 35.9k
Yung‐Jue Bang South Korea 87 20.9k 1.0× 17.1k 1.4× 10.8k 1.1× 4.0k 0.6× 7.6k 1.4× 610 37.1k
Elizabeth A. Eisenhauer Canada 61 15.2k 0.7× 12.7k 1.0× 12.0k 1.2× 2.8k 0.4× 4.1k 0.8× 213 41.9k
Herbert I. Hurwitz United States 71 17.8k 0.8× 7.8k 0.6× 8.0k 0.8× 3.0k 0.4× 3.7k 0.7× 319 26.8k

Countries citing papers authored by John D. Hainsworth

Since Specialization
Citations

This map shows the geographic impact of John D. Hainsworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Hainsworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Hainsworth more than expected).

Fields of papers citing papers by John D. Hainsworth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John D. Hainsworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Hainsworth. The network helps show where John D. Hainsworth may publish in the future.

Co-authorship network of co-authors of John D. Hainsworth

This figure shows the co-authorship network connecting the top 25 collaborators of John D. Hainsworth. A scholar is included among the top collaborators of John D. Hainsworth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John D. Hainsworth. John D. Hainsworth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Javle, Milind, Mitesh J. Borad, Nilofer S. Azad, et al.. (2021). Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. The Lancet Oncology. 22(9). 1290–1300. 251 indexed citations breakdown →
2.
Friedman, Claire F., John D. Hainsworth, Razelle Kurzrock, et al.. (2021). Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discovery. 12(3). 654–669. 56 indexed citations
3.
Yardley, Denise A., Robyn R. Young, Kerin B. Adelson, et al.. (2021). A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer. 22(3). 269–278. 9 indexed citations
4.
Armstrong, Andrew J., Andrew B. Nixon, Qian Yang, et al.. (2021). Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 27(12). 3317–3328. 18 indexed citations
5.
Yardley, Denise A., N. W. Peacock, Brooke Daniel, et al.. (2020). Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 180(3). 647–655. 5 indexed citations
6.
Casulo, Carla, Michelle Byrtek, Keith Dawson, et al.. (2015). Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. Journal of Clinical Oncology. 33(23). 2516–2522. 509 indexed citations breakdown →
7.
Strosberg, Jonathan, James C. Yao, Emilio Bajetta, et al.. (2015). Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET) : A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data. Pancreas. 44(2). 359–359. 1 indexed citations
8.
Yardley, Denise A., et al.. (2014). Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute. Clinical Breast Cancer. 15(4). 251–258. 4 indexed citations
9.
Yardley, Denise A., et al.. (2014). Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial. Breast Cancer Research and Treatment. 148(3). 535–540. 1 indexed citations
10.
Dreicer, Robert, David B. MacLean, Ajit Suri, et al.. (2014). Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 20(5). 1335–1344. 34 indexed citations
11.
Sekulić, Aleksandar, Michael R. Migden, Anthony E. Oro, et al.. (2012). Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine. 366(23). 2171–2179. 1011 indexed citations breakdown →
12.
Yardley, Denise A., Eric Raefsky, Dana S. Thompson, et al.. (2011). Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer. Clinical Breast Cancer. 11(5). 297–305. 42 indexed citations
13.
Yardley, Denise A., Howard A. Burris, N. W. Peacock, et al.. (2010). A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Research and Treatment. 123(2). 471–475. 21 indexed citations
14.
Hainsworth, John D., David R. Spigel, Howard A. Burris, et al.. (2010). Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology. 28(13). 2131–2136. 135 indexed citations
15.
Infante, Jeffrey R., Denise A. Yardley, Howard A. Burris, et al.. (2009). Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer. 9(1). 23–28. 15 indexed citations
16.
Yardley, Denise A., Howard A. Burris, F. Anthony Greco, et al.. (2009). Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer. Clinical Breast Cancer. 9(3). 178–183. 21 indexed citations
17.
Burris, Howard A., Denise A. Yardley, Suzanne F. Jones, et al.. (2004). Phase II Trial of Trastuzumab Followed by Weekly Paclitaxel/Carboplatin As First-Line Treatment for Patients With Metastatic Breast Cancer. Journal of Clinical Oncology. 22(9). 1621–1629. 87 indexed citations
18.
Pater, Joseph L., W. Lofters, Benny Zee, et al.. (1997). The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Annals of Oncology. 8(2). 181–185. 54 indexed citations
19.
Hainsworth, John D.. (1993). The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer. Annals of Oncology. 4. S37–S40. 3 indexed citations
20.
Johnson, David H., Russell F. DeVore, F. Anthony Greco, et al.. (1992). Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.. PubMed. 19(1 Suppl 2). 50–6. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janet Dancey Breakdown of academic impact, for papers by Howard A. Burris Breakdown of academic impact, for papers by Armando Santoro Breakdown of academic impact, for papers by Richard Kaplan Breakdown of academic impact, for papers by Salvatore Siena Breakdown of academic impact, for papers by M. van Glabbeke Breakdown of academic impact, for papers by Heinz‐Josef Lenz Breakdown of academic impact, for papers by Yung‐Jue Bang Breakdown of academic impact, for papers by Elizabeth A. Eisenhauer Breakdown of academic impact, for papers by Herbert I. Hurwitz
Rankless by CCL
2026